Use of Rapamycin for Cognitive Optimization Among Patients with Alzheimer’s Disease and Dementia

Principal Investigator:

Dr. Sheldon Jordan

MD, The Regenesis Project

Dr. Jordan specializes in advanced imaging techniques, interventions for brain and nerve injury, anti-aging of the brain, and regenerative medicine. As chief investigator for numerous institutional review board-approved clinical research projects, Dr. Jordan actively endeavors to advance the boundaries of neurological care.

Study Abstract:

Previous research has reported the beneficial effects of sirolimus (rapamycin) administration in numerous animal models of aging and neurodegeneration, including Alzheimer’s disease.  To address a lack of clinical and patient-reported data, this Circle aims to evaluate the development of Alzheimer’s disease among patients partaking in a rapamycin treatment plan.  Following the administration of rapamycin, patients will complete study assessments, including the Montreal Cognitive Assessment (MoCA) test and Quick Dementia Rating Scale (QDRS), on a quarterly basis for 12 months.

Study Type:

Interventional

Circle Benefits:
  • Longitudinal, real-world safety and efficacy assessment of rapamycin prescription.
  • Regular Circle hours discussing Dr. Jordan’s evidence-based analyses and protocols.
  • Remote, turnkey, administration of the full MoCA assessment.
  • Targeted, automated caregiver reminders for medication adherence and lab work.
Real-World Data Surveys:
  • Montreal Cognitive Assessment (MoCA) Test - Version 8.1
  • Quick Dementia Rating Scale (QDRS)
  • Multidimensional Fatigue Inventory (MFI-20)
  • Patient Health Questionnaire (PHQ-9)
  • General Anxiety Disorder Questionnaire (GAD-7)
Circle Type:

Private Circle

Interested in learning more about this Circle?

Use of Rapamycin for Cognitive Optimization Among Patients with Alzheimer’s Disease and Dementia

Circle Objective Abstract:

Previous research has reported the beneficial effects of sirolimus (rapamycin) administration in numerous animal models of aging and neurodegeneration, including Alzheimer’s disease.  To address a lack of clinical and patient-reported data, this Circle aims to evaluate the development of Alzheimer’s disease among patients partaking in a rapamycin treatment plan.  Following the administration of rapamycin, patients will complete study assessments, including the Montreal Cognitive Assessment (MoCA) test and Quick Dementia Rating Scale (QDRS), on a quarterly basis for 12 months.

Real-World Data Surveys:

Comparative MoCA scores at 6 and 12 months post-intervention for patient cohorts defined by type of medication or other therapy administered.

MoCA, QDRS, MFI-20, PHQ-9, GAD-7

Intervention:

Neurologists, psychiatrists, geriatricians, primary care physicians, and other clinicians.

Circle Benefits:
  • Longitudinal, real-world safety and efficacy assessment of rapamycin prescription.
  • Regular Circle hours discussing Dr. Jordan’s evidence-based analyses and protocols.
  • Remote, turnkey, administration of the full MoCA assessment.
  • Targeted, automated caregiver reminders for medication adherence and lab work.

Streamlined patient enrollment, real-world data capturing, heightened recognition, prominence and collaboration

Circle Type:

Private Circle

Interested in learning more about this Circle?

CIRCLE LIBRARY

CIRCLE NAME

Total Knee Arthroplasty Outcome-Based Performance Measure

SURVEYS

OUTCOMES SURVEYS

VAS
KOOS Jr.
VR-12 (compliant with CMS/IQR Requirements)

CLINICAL SURVEYS

As specified by Provider

THIS CIRCLE IS FOR:

Provider Receiving CMS Reimbursement For TKAs

CMS will soon penalize providers performing total knee replacements which do not collect specified outcomes data from at least 50% of qualifying patients.

Other Providers Performing TKAs

Private insurance companies and other payers within and outside the U.S. will follow the CMS lead in requiring high patient compliance in reporting long-term TKA outcomes.

WHY CIRCLES

Patented technology
HIPAA, GDPR, GCP and Part 11 compliant
Multilingual
Scalable
Easily export to, integrate with, existing systems
Robust reporting functions
Illustrative Materials
Minimal administrative and clinical burden
Accommodates surgical variations
All data accessible 24/7 from any device
Allows extensive customization
Inherent collaboration among peers
Improves clinical decision-making
Adjustable outcomes alerts
Regular reports on key metrics
Automatic patient consent capture
Illustrative Materials
Sustained onboarding and follow-up processes
Communication of condition and protocol education materials *
Regular progress reports *
Cohort comparisons *
Newsletters, other patient communications *
*  Provider defined
Illustrative Materials
Clear ownership of validated anonymized datasets
Copyrightable
Right to publish
Right to monetize
Illustrative Materials
Not a point solution, but a strategic initiative
Easily extensible and scalable
Accommodates Health Equity initiatives
Accommodates CMS Hospital Value Program and other Value-Based Care initiatives
Clinical Grade
Patented technology
HIPAA, GDPR, GCP and Part 11 compliant
Multilingual
Scalable
Robust reporting functions
Easily export to, integrate with, existing systems
Interested in this Circle?

If you have any questions, please contact us.

ADDITIONAL RESOURCES